SAB Biotherapeutics, Inc.

NasdaqCM:SABS Rapporto sulle azioni

Cap. di mercato: US$28.2m

SAB Biotherapeutics Gestione

Gestione criteri di controllo 4/4

SAB Biotherapeutics Il CEO è Samuel Reich, nominato in Jan2024, e ha un mandato di meno di un anno. la retribuzione annua totale è $ 768.40K, composta da 45.5% di stipendio e 54.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.24% delle azioni della società, per un valore di $ 67.01K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 4.4 anni.

Informazioni chiave

Samuel Reich

Amministratore delegato

US$768.4k

Compenso totale

Percentuale dello stipendio del CEO45.5%
Mandato del CEOless than a year
Proprietà del CEO0.2%
Durata media del management2.5yrs
Durata media del Consiglio di amministrazione4.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Samuel Reich rispetto agli utili di SAB Biotherapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$768kUS$350k

-US$42m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$985kUS$350k

-US$19m

Sep 30 2022n/an/a

-US$22m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$3mUS$53k

-US$17m

Compensazione vs Mercato: La retribuzione totale di Samuel ($USD 768.40K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 652.28K ).

Compensazione vs guadagni: La retribuzione di Samuel è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Samuel Reich (49 yo)

less than a year

Mandato

US$768,396

Compensazione

Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Samuel Reich
CEO & Executive Chairmanless than a yearUS$768.40k0.24%
$ 67.0k
Eddie Sullivan
Co-Founder10.8yrsUS$807.76k5.67%
$ 1.6m
Christine Hamilton
Co-Founder & Independent Directorno dataUS$25.00k5.63%
$ 1.6m
Christoph Bausch
Executive VP & COO2.5yrsUS$549.32k1.08%
$ 305.2k
Alexandra Kropotova
Executive VP & Chief Medical Officer2.4yrsUS$921.58k0%
$ 0
Edward Hamilton
Co-Founder & Board Observerno dataNessun dato3.15%
$ 890.2k
Carlos Carillo
Senior Vice President of Regulatory Affairs3.4yrsNessun datoNessun dato

2.5yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di SABS è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Samuel Reich
CEO & Executive Chairman4yrsUS$768.40k0.24%
$ 67.0k
Eddie Sullivan
Co-Founderno dataUS$807.76k5.67%
$ 1.6m
Christine Hamilton
Co-Founder & Independent Director10.8yrsUS$25.00k5.63%
$ 1.6m
Edward Hamilton
Co-Founder & Board Observer3.1yrsNessun dato3.15%
$ 890.2k
William Polvino
Independent Director5.8yrsUS$25.00k0%
$ 0
Jeffrey Spragens
Independent Director4yrsUS$25.00k0.43%
$ 120.9k
David Link
Independent Vice Chairman6.8yrsUS$25.00k0.062%
$ 17.5k
Erick Lucera
Independent Director1.6yrsUS$26.93k0%
$ 0
Jim Robl
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Arturo Casadevall
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Haller
Member of the Clinical Advisory Board & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Stephen Gitelman
Member of Scientific Advisory Board & Member of Clinical Advisory Board4.8yrsNessun datoNessun dato

4.4yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SABS sono considerati esperti (durata media dell'incarico 4.4 anni).